Acamprosate modulates experimental autoimmune encephalomyelitis

Objective This pilot study aimed to determine the efficacy of acamprosate ( N -acetyl homotaurine) in reducing the pathological features of experimental autoimmune encephalomyelitis (EAE) which is an animal model for multiple sclerosis (MS). Background The amino acid taurine has multiple biological activities including immunomodulation and neuromodulation. The synthetic acetylated taurine derivative, acamprosate, which crosses the blood–brain barrier more readily compared to taurine, is currently being used for the prevention of alcohol withdrawal symptoms associated with enhanced glutamatergic receptor function and GABA receptor hypofunction. Methods EAE was induced in C57BL/6 female mice with myelin oligodendrocyte glyocoprotein, amino acid 35–55. Mice were treated with 20, 100 and 500 mg/kg acamprosate for 21 days. Results Neurological scores at disease peak were reduced by 21, 64 and 9% in the 20, 100 and 500 mg/kg groups, respectively. Neurological improvement in the 100 mg/kg group correlated with a reduction in numbers of inflammatory lesions and the extent of CNS demyelination. Blood TNF-α levels were significantly reduced in the 500 mg/kg group. Discussion Acamprosate and other taurine analogs have a potential for future MS therapy.